OrbiMed

OrbiMed is one of the world's largest healthcare-dedicated investment firms. They invest across the full spectrum of healthcare, from early-stage venture capital to public equities and credit, with deep expertise in biopharmaceuticals, medical devices, and healthcare services.

Location
New York, New York, USA
Founded
1989
AUM
$18B+
Investment Range
$10M - $200M+
Portfolio Companies
1
Focus
biotech-focused
Fund Stages
seed, series-a, series-b, series-c, growth

Investment Thesis

OrbiMed invests in companies across the healthcare spectrum, from drug discovery to healthcare services. Their multi-stage approach allows them to support companies throughout their lifecycle, from formation through IPO and beyond, bringing deep industry expertise and an extensive network to portfolio companies.

Team

Partners / Managing Directors (Health & Bio Focus)

  • Sven Hoppe, MD, PhD - Managing Partner
  • Carl Gordon, PhD, CFA - Managing Partner
  • Jonathan Silverstein - Managing Partner
  • Carter Neild - Managing Partner
  • Geoffrey Hsu - Managing Partner

Other Key Team Members

  • Large global team with offices in NYC, San Francisco, Hong Kong, Mumbai
  • Investment team includes MDs, PhDs, former pharma executives

Focus Areas

  • Biopharmaceuticals
  • Biotechnology
  • Medical devices
  • Healthcare services
  • Healthcare IT
  • Diagnostics
  • Life science tools

Notable Investments

  • Mirador Therapeutics - $400M funding round (2024)
  • One of the most active healthcare investors globally
  • Strong track record across therapeutic areas

Notable Exits

  • Numerous IPOs annually across biopharma
  • Multiple M&A exits above $1B
  • Leading returns in healthcare venture

Sources

Portfolio Companies

NameLocationFoundedCategories
Mirador TherapeuticsSan Diego, California, USA2023
therapeuticsbiotech+3